Boston Scientific Shipped Defective Taxus Stents, FDA Warning Letter Says
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's third warning letter since May faults the firm for shipping defective Taxus drug-eluting stents and not adequately addressing the quality system problem once it was discovered